Major cardiovascular events increase in long-term proprotein convertase subtilisin/kexin type 9 inhibitors therapy: the Tuscany cost-effective study.
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
medline:
2
10
2023
pubmed:
29
9
2023
entrez:
29
9
2023
Statut:
ppublish
Résumé
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a breakthrough in the treatment of hypercholesterolemia. The aim of this study was to perform a multicentre prospective analysis on the effects of PCSK9i since their distribution in Italy. During the study period (July 2017 to February 2022) 246 patients (mean age 61 ± 11 years, male 73%) who were evolocumab (142/246) or alirocumab (104/246) new users were enrolled in the CERTI (Costo Efficacia Regione Toscana Inibitori PCSK9) study. Lipid value, adverse events (AEs), major cardiovascular events (MACEs) and intima-media thickness were analysed. PCSK9i therapy allowed a significant improvement in patients' lipid profile [total cholesterol -35%, P < 0.001; triglycerides -9%, P < 0.05; low-density lipoprotein (LDL) cholesterol -51%, P < 0.001; Lp(a) levels -4%, P < 0.05], maintained during the follow-up. No significant variations in intima-media thickness were observed. In the subgroup of patients with more than 1 year of PCSK9i therapy (165/246 patients) we highlighted: a 66% reduction in MACEs compared with the year before recruitment; a progressive increase in MACEs during the follow-up (MACEs event/rate at first year 0.08 vs. MACEs event/rate at year 5: 0.47); a patients cluster with late MACEs older, with higher prevalence of hypertension, smoking habit and peripheral vascular disease. During the follow-up, we recorded AEs in 31% of patients, which mainly resulted in reduction/discontinuation of lipid-lowering therapy for 50 patients or in discontinuation/shift of PCSK9i (respectively 8 and 6 cases). Our data agree with the large evidence on the effectiveness/tolerability of PCSK9i therapy; however, although PCSK9i represents a good cholesterol-lowering therapeutic option, our study shows a progressive increase in MACEs during the late follow-up that deserve further research.
Sections du résumé
BACKGROUND
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a breakthrough in the treatment of hypercholesterolemia. The aim of this study was to perform a multicentre prospective analysis on the effects of PCSK9i since their distribution in Italy.
METHODS
During the study period (July 2017 to February 2022) 246 patients (mean age 61 ± 11 years, male 73%) who were evolocumab (142/246) or alirocumab (104/246) new users were enrolled in the CERTI (Costo Efficacia Regione Toscana Inibitori PCSK9) study. Lipid value, adverse events (AEs), major cardiovascular events (MACEs) and intima-media thickness were analysed.
RESULTS
PCSK9i therapy allowed a significant improvement in patients' lipid profile [total cholesterol -35%, P < 0.001; triglycerides -9%, P < 0.05; low-density lipoprotein (LDL) cholesterol -51%, P < 0.001; Lp(a) levels -4%, P < 0.05], maintained during the follow-up. No significant variations in intima-media thickness were observed. In the subgroup of patients with more than 1 year of PCSK9i therapy (165/246 patients) we highlighted: a 66% reduction in MACEs compared with the year before recruitment; a progressive increase in MACEs during the follow-up (MACEs event/rate at first year 0.08 vs. MACEs event/rate at year 5: 0.47); a patients cluster with late MACEs older, with higher prevalence of hypertension, smoking habit and peripheral vascular disease. During the follow-up, we recorded AEs in 31% of patients, which mainly resulted in reduction/discontinuation of lipid-lowering therapy for 50 patients or in discontinuation/shift of PCSK9i (respectively 8 and 6 cases).
CONCLUSION
Our data agree with the large evidence on the effectiveness/tolerability of PCSK9i therapy; however, although PCSK9i represents a good cholesterol-lowering therapeutic option, our study shows a progressive increase in MACEs during the late follow-up that deserve further research.
Identifiants
pubmed: 37773882
doi: 10.2459/JCM.0000000000001546
pii: 01244665-202311000-00006
doi:
Substances chimiques
Anticholesteremic Agents
0
Cholesterol, LDL
0
PCSK9 Inhibitors
0
PCSK9 protein, human
EC 3.4.21.-
Proprotein Convertase 9
EC 3.4.21.-
Subtilisins
EC 3.4.21.-
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
808-814Informations de copyright
Copyright © 2023 Italian Federation of Cardiology - I.F.C. All rights reserved.
Références
Pećin I, Hartgers ML, Hovingh GK, Dent R, Reiner Ž. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: the role of PCSK9 inhibitors. Eur J Prev Cardiol 2017; 24:1383–1401.
Gazzetta Ufficiale n.31 del 07 febbraio 2017. Classificazione del medicinale per uso umano «Repatha», ai sensi dell’art. 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 172/2017) (17A01047) 2017. Gazzetta Ufficiale n.24 del 06 marzo 2017. Classificazione del medicinale per uso umano «Praluent» ai sensi dell’art. 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 256/2017) (17A01583) 2017.
Piccinni C, Antonazzo IC, Maggioni AP, et al. PCSK9 inhibitors’ new users: analysis of prescription patterns and patients’ characteristics from an Italian Real-world Study. Clin Drug Investig 2020; 40:173–181.
Sampietro T, Sbrana F, Bigazzi F, et al. Cost-effectiveness study on the use of PCSK9 inhibitors in Tuscany – CERTI Study. Giornale Italiano dell’Arteriosclerosi 2020; 11:30–47.
Mach F, Baigent C, Catapano AL, et al. Scientific Document E.S.C. Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41:111–188.
Breiman L. Random forests. Mach Learn 2001; 45:5–32.
Sbrana F, Pino BD, Bigazzi F, et al. A large Italian cohort on proprotein convertase subtilisin/kexin type 9 inhibitors. Eur J Prev Cardiol 2020; 27:2284–2287.
Sampietro T, Sbrana F, Dal Pino B, Bigazzi F, Palmieri C, Berti S. Acute coronary syndrome and lipid-lowering therapy in a realistic diagnostic-therapeutic care pathway. Pharmacol Res 2021; 171:105763.
Nanchen D, Carballo D, Bilz S, et al. Effectiveness, adherence, and safety of evolocumab in a Swiss multicenter prospective observational study. Adv Ther 2022; 39:504–517.
Sbrana F, Dal Pino B, Bigazzi F, et al. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: after PCSK-9 antibodies what else? Eur J Prev Cardiol 2017; 24:1528–1531.
D’Erasmo L, Commodari D, Di Costanzo A, et al. Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: a retrospective, single center, observational study. Nutr Metab Cardiovasc Dis 2020; 30:2027–2035.
Zafrir B, Egbaria A, Stein N, Elis A, Saliba W. PCSK9 inhibition in clinical practice: treatment patterns and attainment of lipid goals in a large health maintenance organization. J Clin Lipidol 2021; 15:202–211. e2.
Iannuzzo G, Buonaiuto A, Calcaterra I, et al. Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: a single center real-world study. Nutr Metab Cardiovasc Dis 2022; 32:684–691.
Crea F. Screening, diagnosis, and treatment of familial hypercholesterolaemia: a call to action. Eur Heart J 2022; 43:3185–3188.
Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic heart disease taking statin treatment. JAMA Int Med 2016; 176:1105–1113.
Saba L, Antignani PL, Gupta A, et al. International Union of Angiology (IUA) consensus paper on imaging strategies in atherosclerotic carotid artery imaging: from basic strategies to advanced approaches. Atherosclerosis 2022; 354:23–40.
Spitthöver R, Röseler T, Julius U, et al. Real-world study: escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis. J Clin Apher 2019; 34:423–433.
Sbrana F, Bigazzi F, Dal Pino B, Toma M, Ripoli A, Sampietro T. Elusive therapeutic effect of PCSK9 inhibitors on lipoprotein(a) levels. Ther Apher Dial 2019; 23:385–386.
Ruscica M, Watts GF, Sirtori CR. PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies. Eur J Prev Cardiol 2019; 26:998–1000.
Dal Pino B, Sbrana F, Bigazzi F, Sampietro T. Is treating severe He FH so easy? A combined treatment between lipoprotein apheresis and PCSK9 inhibitors. Transfus Apher Sci 2021; 60:103258.
Vicente-Valor J, García-González X, Ibáñez-García S, et al. PCSK9 inhibitors revisited: effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort. Biomed Pharmacother 2022; 146:112519.
Casula M, Gazzotti M, Bonaiti F, et al. PROSISA Study Group. Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. J Intern Med 2021; 290:116–128.
Dal Pino B, Bigazzi F, Sbrana F. Inclisiran and lipoprotein apheresis in statin intolerance heterozygous FH patients: a case series. Ther Apher Dial 2023; doi: 10.1111/1744-9987.14025. [Online ahead of print].
doi: 10.1111/1744-9987.14025.
Wang HF, Mao YC, Xu XY, et al. Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: a meta-analysis focusing on the number needed to treat. Front Cardiovasc Med 2022; 9:1016802.